A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.
Tirzepatide 15mg
Dual GLP-1 / GIP Incretin Agonist — 15mg Presentation
Compound Specifications
Tirzepatide 15mg
Dual GLP-1 / GIP Incretin Agonist — 15mg Presentation
Tirzepatide 15mg is a dual GIP and GLP-1 receptor co-agonist presented in a 3mL vial. In clinical trials, simultaneous activation of both incretin pathways demonstrated significant body weight reduction and improvements in glycemic and metabolic markers under medical supervision.
Simultaneously engages GIP and GLP-1 receptors, enhancing pancreatic beta-cell sensitivity, supporting adipose lipid metabolism, and minimizing nausea often seen with single-pathway agonists.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Administered once weekly subcutaneously, titrated under physician direction to the 15mg maintenance presentation.
Frequently Asked Clinical Questions
Where does the 15mg presentation fit in a Tirzepatide titration?
The 15mg presentation is typically used as a maintenance dose after a physician-guided titration from the 2.5mg starting dose.